Drug Development Pipeline
PTI-428 + PTI-801 + PTI-808
Restore CFTR Function
PTI-428 + PTI-801 + PTI-808 is a combination therapy combining three CFTR modulators.
PTI-801 is a corrector, a type of modulator designed to fix the defective CFTR protein so that it can move to the proper place on the cell surface. PTI-808 is a potentiator. Once CFTR protein reaches the cell surface, potentiators help facilitate the opening of the chloride channel to allow chloride and sodium (salt) to move in and out of the cell. PTI-428 is a new type of modulator called an amplifier. Amplifiers increase the amount of CFTR protein in the cell. This makes more CFTR protein available for other therapies, such correctors and potentiators, to work on.
Multiple phase 2 studies are being conducted to test the safety and effectiveness of these drugs, both alone and in combination with each other.
This program is sponsored by Proteostasis Therapeutics. It is being conducted through the Therapeutics Development Network.
Recent PTI-428 + PTI-801 + PTI-808 Studies
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More